American Century Companies Inc. Grows Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

American Century Companies Inc. lifted its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 14.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,274,067 shares of the medical equipment provider's stock after buying an additional 157,731 shares during the quarter. American Century Companies Inc. owned approximately 0.56% of Hologic worth $91,848,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in HOLX. General Partner Inc. purchased a new position in shares of Hologic in the fourth quarter worth $26,000. Venturi Wealth Management LLC grew its stake in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares during the period. First Horizon Advisors Inc. lifted its stake in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 134 shares during the period. EverSource Wealth Advisors LLC raised its position in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC lifted its position in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Remove Ads

Hologic Trading Down 1.6 %

HOLX traded down $1.00 during trading hours on Friday, reaching $61.32. The company's stock had a trading volume of 1,110,999 shares, compared to its average volume of 1,809,690. Hologic, Inc. has a fifty-two week low of $60.34 and a fifty-two week high of $84.67. The business's 50-day moving average is $65.41 and its 200-day moving average is $73.50. The stock has a market cap of $13.76 billion, a PE ratio of 19.34, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the subject of several recent analyst reports. Leerink Partnrs downgraded shares of Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. William Blair restated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Stephens restated an "overweight" rating and issued a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Royal Bank of Canada decreased their price objective on Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research report on Thursday, February 6th. Finally, BNP Paribas raised shares of Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Hologic currently has a consensus rating of "Hold" and a consensus price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.